Study | When to increase treatment | How to increase treatment | |||||
---|---|---|---|---|---|---|---|
% Level | Traffic light | No of action point levels | PEF or symptom based | ICS | OCS | ||
NS = not stated; PEF = peak expiratory flow; ICS = inhaled corticosteroids; OCS = oral corticosteroids. | |||||||
*Based on Beasley et al.47 | |||||||
†Based on Charlton.48 | |||||||
‡Based on BTS.49 | |||||||
§Based on Woolcock.50 | |||||||
¶Based on Beasley “credit card plan”. | |||||||
**Personal best PEF. | |||||||
††Predicted PEF. | |||||||
Cote et al8 | 85** | Yes | 4 | PEF/symptom | BDP 2000 μg | Yes | |
Cowie et al9* | 70** | No | 4 | PEF/symptom | Double | Yes | |
Gallefoss et al10–14 | 80** | Yes | 4 | PEF | Double/triple | Yes | |
Ghosh et al15* | 70** | No | 4 | PEF | Double | Yes | |
Grampian16 | NS | NS | NS | PEF | NS | Yes | |
Hayward et al17 | 70** | NS | 2 | PEF | NS | Yes | |
Heard et al18† | 70†† | Yes | 4 | NS† | Double | Yes | |
Ignacio-Garcia19 | 70** | No | 3 | PEF | Double | Yes | |
Jones et al20* | 75** | No | 4 | PEF | Double | Yes | |
Lahdensuo et al21 | 85** | No | 2 | PEF | Double | Yes | |
Levy et al22¶ | 80†† | Yes | 3 | PEF/symptom | Double | Yes | |
Moudgil et al23‡ | 80†† | No | 4 | PEF/symptom | Double | Yes | |
Perneger et al24‡ | 80†† | NS | 4 | PEF/symptom | Double | Yes | |
Schermer et al25 | 80** | NS | 3 | PEF | Double or commence | Yes | |
Sommaragua et al26 | 80†† | No | 3 | PEF | No | Yes | |
Yoon et al27§ | 80†† | No | 3 | PEF/symptom | Double | Yes | |
Zeiger et al28 | NS | NS | NS | PEF | NS | Yes |